ADX-100 FDA Approval Date
Resolves: FDA approval of ADX-100 for dry eye disease.
sec_filing· Regulatory Filings
ADX-100 FDA Approval Date
Market overview
Derived from Aldeyra Therapeutics, Inc. (ALDX) (CIK 0001341235) 8-K filing analysis
Regulatory Filings prediction market
- Implied probability (Yes)
- 85%
- Closes
- 2027-03-29
About this prediction
Resolution criteria
FDA approval of ADX-100 for dry eye disease.
More Regulatory Filings markets
- Timely Filing of 2026 10-K Report — 95% Yes
- Phase 3 Interim Data Readout — 55% Yes
- Silexion Therapeutics Potential IND/NDA Filing — 70% Yes
- Post-Merger Regulatory Compliance — 90% Yes
- ANAB: IND Filing from New Collaboration — 60% Yes
- Potential Regulatory Scrutiny — 40% Yes
- Antitrust and Regulatory Approval for WEAV Acquisition — 95% Yes
- Bunker Hill Mining Corp. (BHLL) receives regulatory approval for TRE acquisition. — 90% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…